The impact of neoadjuvant weekly ixabepilone for high-risk prostate cancer: A phase I/II clinical trial.
Layton J, Plette A, Renzulli J, Miller E, Safran H, Mega A. The impact of neoadjuvant weekly ixabepilone for high-risk prostate cancer: A phase I/II clinical trial. Journal Of Clinical Oncology 2012, 30: 158-158. DOI: 10.1200/jco.2012.30.5_suppl.158.Peer-Reviewed Original ResearchHigh-risk prostate cancerPhase I/II clinical trialsPathologic complete responsePositive surgical marginsWeekly ixabepiloneProstate cancerAdverse eventsPSA responseComplete responseSurgical marginsPSA valuesClinical trialsPositive regional lymph nodesCessation of chemotherapyPre-operative PSAPretreatment Gleason scorePhase II studyRisk prostate cancerHigh-risk diseaseRegional lymph nodesBiochemical recurrence rateMetastatic prostate cancerTime of reviewCT3 diseaseGleason 8